lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
== Operations == KCI is composed of three business units: Active Healing Solutions, LifeCell and Therapeutic Support Systems, that operate in the wound care, regenerative medicine and therapeutic support systems markets. The largest of these business units is dedicated to wound care primarily negative pressure wound therapy for the treatment of traumatic wounds, pressure ulcers, chronic wounds and diabetic ulcers but also assistance with surgery. The therapeutic support systems developed and supplied by KCI are largely for the treatment and prevention of complications associated with patient immobility. These include support surfaces for hospital beds and home patients designed to address pulmonary complications in immobile patients. KCI also develops specialty beds for use in hospitals or in long-term care facilities. KCI expanded into the regenerative medicine market in 2008. Through subsidiary company LifeCell Corporation, KCI develops and supplies tissue-based products. These include tissue-based treatments used in surgical procedures to repair soft-tissue.
== Computer System Validation == This requirement has naturally expanded to encompass computer systems used both in the development and production of, and as a part of pharmaceutical products, medical devices, food, blood establishments, tissue establishments, and clinical trials. In 1983 the FDA published a guide to the inspection of Computerized Systems in Pharmaceutical Processing, also known as the 'bluebook'. Recently both the American FDA and the UK Medicines and Healthcare products Regulatory Agency have added sections to the regulations specifically for the use of computer systems. In the UK, computer validation is covered in Annex 11 of the EU GMP regulations (EMEA 2011). The FDA introduced 21 CFR Part 11 for rules on the use of electronic records, electronic signatures (FDA 1997). The FDA regulation is harmonized with ISO 8402:1994, which treats "verification" and "validation" as separate and distinct terms. On the other hand, many software engineering journal articles and textbooks use the terms "verification" and "validation" interchangeably, or in some cases refer to software "verification, validation, and testing (VV&T)" as if it is a single concept, with no distinction among the three terms.
=== 2019 recall of Ranitidine products === In 2019, Dr. Reddy's recalled all ranitidine products in the US market due to contamination with the carcinogen N-nitrosodimethylamine (NDMA). Months later, all brands of ranitidine were recalled and it was taken off the US market, as the carcinogen was an unavoidable byproduct.
Treponema pallidum, formerly known as Spirochaeta pallida, is a microaerophilic, gram-negative, spirochaete bacterium with subspecies that cause the diseases syphilis, bejel (also known as endemic syphilis), and yaws. It is known to be transmitted only among humans and baboons. T. pallidum can enter the host through mucosal membranes or open lesions in the skin and is primarily spread through sexual contact. It is a helically coiled microorganism usually 6–15 μm long and 0.1–0.2 μm wide. T. pallidum's lack of both a tricarboxylic acid cycle and processes for oxidative phosphorylation results in minimal metabolic activity. As a chemoorganoheterotroph, Treponema pallidum is an obligate parasite that acquires its glucose carbon source from its host. Glucose can be used not only as a primary carbon source but also in glycolytic mechanisms to generate ATP needed to power the bacterium given its minimal genome. The treponemes have cytoplasmic and outer membranes. Using light microscopy, treponemes are visible only by using dark-field illumination. T. pallidum consists of three subspecies, T. p. pallidum, T. p. endemicum, and T. p. pertenue, each of which has a distinct related disorder. The ability of T. pallidum to avoid host immune defenses has allowed for stealth pathogenicity. The unique outer membrane structure and minimal expression of surface proteins of T. pallidum has made vaccine development difficult. Treponema pallidum can be treated with high efficacy by antibiotics that inhibit bacterial cell wall synthesis such as the beta-lactam antimicrobial penicillin-G.
Sources: en.wikipedia.org
This test showed the compound later named fluoxetine to be the most potent and selective inhibitor of serotonin reuptake of the series. Introduction of fluoxetine to the market is hailed as a miracle drug for the treatment of depression because it had fewer adverse effects, simpler dosing strategies and greater margin of safety when overdoses were consumed and thus it had better adherence, compared to the older antidepressants (TCAs and MAOIs). Fluoxetine paved the way for the next generation of SSRIs, serving as a prototype for them. Since then the number of drugs in the SSRI class has become bigger and there are now six (fluoxetine, paroxetine, citalopram, escitalopram, sertraline, and fluvoxamine), as demonstrated in table 1.
== Cryogenic cooling == Another refrigeration system sometimes used where the journey time is short is total loss refrigeration, in which frozen carbon dioxide ice (or sometimes liquid nitrogen) is used for cooling. The cryogenically frozen gas slowly evaporates, and thus cools the container and is vented from it. The container is cooled for as long as there is frozen gas available in the system. These have been used in railcars for many years, providing up to 17 days temperature regulation. Whilst refrigerated containers are not common for air transport, total loss dry ice systems are usually used. These containers have a chamber which is loaded with solid carbon dioxide and the temperature is regulated by a thermostatically controlled electric fan, and the air freight versions are intended to maintain temperature for up to around 100 hours. Full-size intermodal containers equipped with these "cryogenic" systems can maintain their temperature for the 30 days needed for sea transport. Since they do not require an external power supply, cryogenically refrigerated containers can be stored anywhere on any vessel that can accommodate "dry" (un-refrigerated) ocean freight containers.
S2CID 17336375. Wickramasinghe, N. C. (2010). "The astrobiological case for our cosmic ancestry". International Journal of Astrobiology. 9 (2): 119–129. Bibcode:2010IJAsB...9..119W. doi:10.1017/S1473550409990413. S2CID 13978227. Wickramasinghe, N.C.; Wallis, J.; Wallis, D.H.; Schild, R.E.; Gibson, C.H. (2012). "Life-bearing planets in the solar vicinity". Astrophysics and Space Science. 341 (2): 295–9. Bibcode:2012Ap&SS.341..295W. doi:10.1007/s10509-012-1092-8. S2CID 120484953. Chandra Wickramasinghe, A Journey with Fred Hoyle: The Search for Cosmic Life, World Scientific Publishing, 2005, ISBN 981-238-912-1 Janaki Wickramasinghe, Chandra Wickramasinghe and William Napier, Comets and the Origin of Life, World Scientific Publishing, 2009, ISBN 981-256-635-X Chandra Wickramasinghe and Daisaku Ikeda, Space and Eternal Life, Journeyman Press, 1998, ISBN 1-85172-060-X
Sources: en.wikipedia.org
=== Phase unknown === AP-002 (AP002) – undefined mechanism of action – opioid-related disorders AP-005 (AP005) – undefined mechanism of action – opioid-related disorders Varenicline implant (SK-2109) – nicotinic acetylcholine receptor agonist – smoking withrawal
== History == Amanita muscaria has been used by humans as a psychoactive drug since ancient times. Muscimol was isolated from Amanita muscaria independently by three different research groups in 1964 and 1965. It was synthesized by Gagneux and colleagues in 1965. The chemical structure of muscimol, along with that of ibotenic acid, was published by Conrad Eugster at the University of Zurich in 1967. Its structural similarity to the neurotransmitter γ-aminobutyric acid (GABA) was quickly recognized and muscimol was shown to have GABA-like actions by Graham Johnston and colleagues in 1968. Subsequently, its actions were shown to be reversed by the GABA receptor antagonist bicuculline in 1971. The effects of muscimol in humans were studied and described by Waser in 1967. Later, ethnobotanist Jonathan Ott further described the effects of muscimol, via Amanita pantherina consumption, in 1976. Danish medicinal chemist Povl Krogsgaard-Larsen and colleagues studied muscimol and synthetic analogues over several decades starting in the 1970s. Other GABAA receptor ligands, such as gaboxadol (THIP) and 4-PIOL, and GABA transporter modulators, such as nipecotic acid and tiagabine, have been derived from muscimol. Many muscimol analogues were developed by Krogsgaard-Larsen and colleagues. Muscimol was encountered online as a novel designer drug in 2023.
=== Gray hair === Low levels of catalase may play a role in the graying process of human hair. Hydrogen peroxide is naturally produced by the body and broken down by catalase. Hydrogen peroxide can accumulate in hair follicles and if catalase levels decline, this buildup can cause oxidative stress and graying. These low levels of catalase are associated with old age. Hydrogen peroxide interferes with the production of melanin, the pigment that gives hair its color.
=== Parkinson's disease === Apomorphine is used for the management of motor fluctuations in Parkinson's disease, particularly for the treatment of "off" episodes. "Off" episodes are periods during which motor symptoms such as rigidity, bradykinesia, or reduced mobility reemerge as the effects of dopaminergic medications wear off. Apomorphine can provide rapid improvement in motor symptoms. Apomorphine is administered in multiple pharmaceutical formulations. Intermittent subcutaneous injection is used as an acute treatment and has been shown to terminate "off" episodes in individuals with motor fluctuations not adequately controlled with oral therapy. Sublingual apomorphine film has been reported in a recent narrative review to produce rapid off‑to‑on conversion and clinically meaningful short‑term improvements in motor scores when used as an on‑demand treatment for off episodes in Parkinson's disease, but an MDS evidence‑based review judged the randomized‑trial data insufficient to conclude that intermittent apomorphine formulations (including sublingual film) provide sustained benefits in disability or quality of life over 12‑week treatment periods. Continuous subcutaneous infusion of apomorphine using a wearable infusion device is also prescribed for individuals with motor fluctuations. Continuous infusion treatment is used in patients whose symptoms are not adequately controlled with oral or transdermal therapies and has been shown to reduce daily "off" time.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.